对于怀孕年龄小的子组在2岁时有差异性发病率,生长和神经发育:INTERBIO-21新生儿研究
Aris T Papageorghiou1, María C Restrepo-Méndez1, Rose McGready2
1Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK; Oxford Maternal & Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK.
American journal of obstetrics and gynecology
|May 25, 2025
概括
对于妊娠年龄来说小 (SGA) 并不是一个单一的条件,而是包括不同的子组. 识别这些子组对于了解SGA婴儿中各种新生儿和儿童健康轨迹至关重要.
科学领域:
- 围产儿医学 围产儿医学
- 发育儿科 发育儿科
- 生殖健康 生殖健康
背景情况:
- 对于妊娠年龄来说小 (SGA) 是一种复杂的围产综合征,与显著的新生儿风险和长期增长和神经发育受损有关.
- 目前基于出生体重的SGA分类无法捕捉其异质性并准确预测未来的健康结果.
研究的目的:
- 识别和表征出不同小于妊娠年龄 (SGA) 新生儿的分组.
- 评估这些SGA子组与新生儿发病率,生长和神经发育结果到2岁之间的关联.
主要方法:
- 一项前性队列研究,涉及6个国家的5153名非SGA和1549名SGA新生儿 (2012-2018).
- 利用两步集群分析来识别基于母亲,胎儿和环境因素的SGA子组.
- 使用后勤回归来评估SGA子组的健康和发育结果,与非SGA新生儿相比,对混因素进行调整.
主要成果:
- 确定了九个不同的SGA子组,包括与严重母亲疾病,以前低出生体重/早产和吸烟有关的子组.
- 在特定子组中的严重SGA新生儿面临新生儿发病率,长期健康问题和生长不良的风险增加.
- 暴露于高血压疾病的中度SGA新生儿显示新生儿发病率和语言和行为的神经发育缺陷的风险更高.
结论:
- 对于妊娠年龄来说小 (SGA) 是一种异质的疾病,有不同的子组.
- 这些子组表现出新生儿发病率,产后生长和神经发育结果的独特模式.
- 根据已识别的子组对SGA进行精细分类,可以提高对相关健康轨迹的理解和管理.
更多相关视频
相关概念视频
01:10Nature and Nurture
19.4K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
19.4K
01:21Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:30Development of Human Microbiota
68
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
68